Literature DB >> 10622721

cDNA cloning, expression and characterization of human prostaglandin F synthase.

T Suzuki-Yamamoto1, M Nishizawa, M Fukui, E Okuda-Ashitaka, T Nakajima, S Ito, K Watanabe.   

Abstract

A cDNA clone of prostaglandin F synthase (PGFS) was isolated from human lung by using cDNA of bovine lung-type PGFS as a probe and its protein expressed in Escherichia coli was purified to apparent homogeneity. The human PGFS catalyzed the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2. The kcat/Km values for PGD2 and 9alpha,11beta-PGF2 were 21000 and 1800 min(-1) mM(-1), respectively, indicating that the catalytic efficiency for PGD2 and 9alpha,11beta-PGF2 was the highest among the various substrates, except for PQ. The PGFS activity in the cytosol of human lung was completely absorbed with antihuman PGFS antiserum. Moreover, mRNA of PGFS was expressed in peripheral blood lymphocytes and the expression in lymphocytes was markedly suppressed by the T cell mitogen concanavalin A. These results support the notion that human PGFS plays an important role in the pathogenesis of allergic diseases such as asthma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622721     DOI: 10.1016/s0014-5793(99)01551-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  42 in total

1.  Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Jeffrey D Winkler; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2011-01-07       Impact factor: 2.823

Review 2.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

Review 3.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 4.  Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.

Authors:  Trevor M Penning; Phumvadee Wangtrakuldee; Richard J Auchus
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

5.  Structure of AKR1C3 with 3-phenoxybenzoic acid bound.

Authors:  Victoria J Jackson; Yuliana Yosaatmadja; Jack U Flanagan; Christopher J Squire
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-27

Review 6.  AKR1C3 as a target in castrate resistant prostate cancer.

Authors:  Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-06       Impact factor: 4.292

7.  Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure.

Authors:  Román A Barraza; Jay W McLaren; Eric M Poeschla
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

8.  An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.

Authors:  Michael C Byrns; Stephan Steckelbroeck; Trevor M Penning
Journal:  Biochem Pharmacol       Date:  2007-09-14       Impact factor: 5.858

9.  PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia.

Authors:  Sofiyan Saleem; Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2009-02-11       Impact factor: 3.911

10.  Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.

Authors:  Pedro Veliça; Nicholas J Davies; Pedro P Rocha; Heinrich Schrewe; Jonathan P Ride; Chris M Bunce
Journal:  Mol Cancer       Date:  2009-12-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.